Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: A randomized controlled trial

JAMA

Volumn 296, Issue 1, 2006, Pages 87-93

  Watkins, Paul B ^a,g   Kaplowitz, Neil ^b   Slattery, John T ^c   Colonese, Connie R ^d   Colucci, Salvatore V ^e   Stewart, Paul W ^f   Harris, Stephen C ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e PURDUE PHARMA L P   (United States)

^f The University of North Carolina at Chapel Hill   (United States)

^g APCF   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; PARACETAMOL; PERCOCET; PLACEBO; ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIET; DRUG BLOOD LEVEL; FEMALE; HOSPITAL PATIENT; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; LONGITUDINAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ACETAMINOPHEN; ADULT; ALANINE TRANSAMINASE; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; SINGLE-BLIND METHOD;

EID: 33745607004     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.1.87     Document Type: Article

References (21)

1. Rosenzweig P, Miget N, Brohler S. Transaminase elevation on placebo during phase 1 trials Br J Clin Pharmacol. 1999;48:19-23.
2. Purkins L. Love Er, Eve MD, Wooldridge CL, Cowan C, Smart TS, Johnson PJ, Rapeport WG. The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a phase I unit. Br J Clin Pharmacol. 2004;57:199-208.
3. Prescott LF. Acetaminophen: past, present, and future. Am J Ther. 2000;7:143-147.
4. Falloon I, Watt DC, Lubbe K, MacDonald A, Sheperd M. N-acetyl-p-amino- phenol (paracetamol, acetaminophen) in the treatment of acute schizophrenia. Psychol Med. 1978;8:495-499.
5. Koennecke HC, Leistner S. Prophylactic antipyretic treatment with acetaminophen in acute ischemic stroke. Neurology. 2001;57:2301-2303.
6. Seideman P, Melander A. Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol. 1988;27:117-122.
7. Seideman P, Melander A. Napoxen and paracetamol compared with naproxen only in coxarthrosis. Acta Orthop Scand. 1993;64:285-288.
8. Bradley JD, Brandt KD, Katz BP, Kalasinski L, Ryan S. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325:87-91.
9. Kwan D, Bartle WR, Walker SE. Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Dig Dis Sci. 1995;40:1951-1955.
10. Lanza FL, Royer GI, Nelson RS, Rack MF, Seckman CE, Schwartz JH. Effect of acetaminophen on human gastric mucosal injury caused by ibuprofen. Gut. 1986;27:440-443.
11. Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39:68-75.
12. Critchley JA, Nimmo GR, Gregson CA, Woolhouse NM, Prescott LF. Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol. 1986;22:649-657.
13. Yin OQ, Tomlinson B, Chow AH, Chow MS. Pharmacokinetics of acetaminophen in Hong Kong Chinese subjects. Int J Pharm. 2001;222:305-308.
14. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransfrase activity in the United States in 1999-2002. Am J Gastroenterol. 2006;101:76-82.
15. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
16. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer. JAMA. 1994;271:992-998.
17. Watkins PB, Seeff LB. Drug-induced liver injury. Hepatology. 2006;43:618-631.
18. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee. JAMA. 2002;287:64-71.
19. Mortensen ME, Cullen JL. Comment: Hepatotoxicity associated with chronic acetaminophen administration in patients without risk factors. Ann Pharmacother. 2002;36:1481-1482.
20. Nikles CJ, Yelland M, Del Mar C, Wilkinson D. The role of paracetamol in chronic pain: an evidence-based approach. Am J Ther. 2005;12:80-91.
21. Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36:1196-1206.